EPIPEN E Z PEN Drug Patent Profile

Which patents cover Epipen E Z Pen, and when can generic versions of Epipen E Z Pen launch?

Epipen E Z Pen is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in EPIPEN E Z PEN is epinephrine. There are twenty-one drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Epipen E Z Pen

A generic version of EPIPEN E Z PEN was approved as epinephrine by BPI LABS on July 29^th, 2014.

Summary for EPIPEN E Z PEN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	15
Patent Applications:	4,202
DailyMed Link:	EPIPEN E Z PEN at DailyMed

Recent Clinical Trials for EPIPEN E Z PEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Washington University School of Medicine	PHASE1
Insignis Therapeutics, Inc.	PHASE1
De Motu Cordis	PHASE1

See all EPIPEN E Z PEN clinical trials

Pharmacology for EPIPEN E Z PEN

Drug Class	Catecholamine alpha-Adrenergic Agonist beta-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Agonists

US Patents and Regulatory Information for EPIPEN E Z PEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	EPIPEN E Z PEN	epinephrine	INJECTABLE;INTRAMUSCULAR	019430-003	Aug 3, 1995		DISCN	No	No

International Patents for EPIPEN E Z PEN

See the table below for patents covering EPIPEN E Z PEN around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	1786491
Cyprus	1117076
Taiwan	200613027
European Patent Office	2179759	Injecteur automatique avec étui protecteur d'aiguille (Automatic injector with needle cover)
Japan	2009090140

Supplementary Protection Certificates for EPIPEN E Z PEN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3678649	LUC00378	Luxembourg		PRODUCT NAME: COMBINAISON D'EPINEPHRINE ET DE DODECYLMALTOSIDE, SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20250211
3678649	2025C/508	Belgium		PRODUCT NAME: COMBINATIE VAN EPINEPHRINE EN DODECYLMALTOSIDE, IN ALLE VORMEN BESCHERMD DOOR HET BASISOCTROOI; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20240823

EPIPEN E Z PEN: Market dynamics and financial trajectory

Last updated: April 26, 2026

What is EPIPEN E Z PEN in the market?

EPIPEN E Z PEN is a brand of epinephrine auto-injectors used for treatment of anaphylaxis. The product competes in the US and select global emergency-injection market where contracting, formulary access, and channel inventory discipline largely determine revenue outcomes.

Commercial structure that drives performance

• Category demand: Tied to anaphylaxis awareness, outpatient prevalence, and school/workplace preparedness mandates.
• Buyer behavior: Hospital and clinic tenders, government programs, and pharmacy benefit management (PBM) formularies drive unit volume more than consumer pull.
• Replacement cycle: Auto-injectors have an expiration-date lifecycle; supply planning and retailer/wholesaler rotations materially affect sell-through timing and quarterly sales volatility.
• Competitive pricing pressure: As more SKUs and generics enter, net price typically declines while share shifts toward preferred products and contract winners.

How do market dynamics translate into sales behavior?

Pricing, access, and channel mechanics

1. Net pricing dominates headline growth
   • Auto-injectors operate with rebates, payer contracts, and distributor terms. Revenue trajectory reflects net sales outcomes more than list price changes.
2. Contracting cycles determine short-run swings
   • Quarterly shipments can surge or dip based on awarded contracts and inventory resets at wholesalers and government distributors.
3. Formulary placement drives durable share
   • Once a product is preferred, repeat institutional purchases tend to stabilize baseline demand.

Regulatory and clinical demand drivers

• Label expansion and awareness generally lift category penetration.
• Safety and device reliability influence tender outcomes, pharmacovigilance scrutiny, and competitive comparisons, which can shift share without large marketing spend.

What is the financial trajectory pattern for this product class?

Epinephrine auto-injectors usually show one of three financial trajectories once a brand enters or changes competitive status:

Trajectory A: Brand peak then net price compression

• Higher early net sales when supply is controlled and reimbursement is favorable.
• Revenue growth slows as competitor offerings increase and procurement moves to lower-cost preferred options.
• Margin compresses as net price falls and promotional intensity rises.

Trajectory B: Share-gain with contracting momentum

• Unit growth outpaces category growth when the brand wins institutional contracts.
• Net sales can remain resilient even as list prices soften, because volume offsets price compression.

Trajectory C: Inventory-driven quarter-to-quarter volatility

• Sell-through is steadier than shipments.
• Revenue fluctuates when expiries, returns, and distributor stock rotations accelerate.

For EPIPEN E Z PEN specifically, the class-level pattern implies:

• Short-run variability tied to contract timing and inventory rotations.
• Mid-term pressure consistent with competitive entry and preferential access redistribution.

Who does EPIPEN E Z PEN compete against?

Competition is dominated by other epinephrine auto-injector brands and lower-cost alternatives where payers and institutions can switch without clinical friction.

Key competitive pressure points

• Device usability and training: tender committees weight ease of use and reliability.
• Price and rebate economics: PBM preferred status often determines purchasing.
• Supply continuity: procurement teams penalize delivery risk.

What financial KPACs should be used to track EPIPEN E Z PEN performance?

Because auto-injector markets are inventory and contract led, the most decision-relevant KPIs are:

KPI	What it signals	Why it matters for trajectory
Net sales trend	Real pricing power and rebate outcome	Reflects contract and payer economics
Units sold / shipments	Channel demand vs stock changes	Explains volatility masked by net pricing
Average net price (ANP)	Competitive pressure level	Early indicator of share erosion
Gross margin	Manufacturing efficiency and mix	Auto-injector margins are sensitive to volume and input costs
Share of preferred formulary positions	Durable access	Predicts baseline demand stability
Backorders / supply performance	Reliability and tender risk	Delivery gaps can shift contracts

Where does the money go: margin and cost drivers

Auto-injector economics are shaped by:

• Component supply (cartridge, syringe, actuator)
• Manufacturing scale and utilization rates
• Regulatory and quality costs
• Distribution and contracting costs (rebates and fees)

Financial trajectory typically reflects:

• Gross margin compression in periods of higher discounting and competitive switching.
• Stabilization when contract volume grows and utilization improves.

What are the market timing signals to monitor?

For EPIPEN E Z PEN, decision-grade timing signals are:

1. Institutional procurement windows
   • School systems, government buyers, and hospital networks cycle purchasing on procurement calendars.
2. Reimbursement rule changes and PBM updates
   • Even minor formulary shifts often show up in net sales with a lag corresponding to contracting and distribution.
3. Expiration and inventory alignment
   • Sales can fall in a quarter when wholesalers reduce stock or when shelf resets occur.

What does the competitive landscape imply for future trajectory?

Given the structure of the auto-injector market:

• Base demand remains recurring (replacement cycle and institutional preparedness).
• Growth is mostly share-driven rather than purely category-driven.
• Pricing pressure persists as procurement favors preferred and lower net-cost offerings.
• Device and supply reliability become differentiators that protect share when competitors face shortages or delivery issues.

Commercial outlook: likely scenarios

Scenario 1: Preferred access holds

• Net sales stay supported by contract renewals and repeat purchases.
• ANP declines gradually, with margin erosion offset by stable volume.

Scenario 2: Share migrates under price pressure

• Units decline or grow slower than expected.
• ANP drops faster due to payer and institutional switching.

Scenario 3: Supply/contract execution improves

• Shipments align with sell-through, reducing volatility.
• Net sales rise in periods where inventory replenishment accelerates.

Key Takeaways

• EPIPEN E Z PEN sits in a contract and formulary-led market where net pricing, preferred status, and inventory rotations drive quarterly revenue patterns.
• Financial trajectory in epinephrine auto-injectors typically shows net price compression over time, with results depending on whether the brand wins or loses preferred contracting.
• Decision-grade KPIs for tracking EPIPEN E Z PEN are net sales trend, units, ANP, gross margin, and formulary/preferred share.
• Forward trajectory is likely share-driven, with durable baseline demand but persistent pressure from competitive economics and procurement switching.

FAQs

1) What primarily drives EPIPEN E Z PEN sales in the US?

Institutional and payer contracting that determines preferred status, plus channel inventory rotation tied to expiration cycles.

2) Why do epinephrine auto-injector revenues often look volatile quarter to quarter?

Shipments can surge or pause based on contract timing and distributor/wholesaler inventory resets, even when underlying sell-through stays steadier.

3) Does this category’s growth come more from demand expansion or share changes?

Mostly from share changes because procurement and preferred access govern incremental volume.

4) What KPI best indicates whether pricing pressure is increasing?

Average net price, observed through net sales trends relative to units.

5) What protects revenue when competitors enter?

Sustained preferred contracting, consistent supply performance, and stable rebate economics that maintain effective net price.

---

References

[1] Bloomberg / Bloomberg Law. (N/A). Product and market coverage (access required).
[2] FDA. (N/A). Auto-injector labeling and regulatory information (access required).
[3] Centers for Medicare & Medicaid Services (CMS). (N/A). Formulary and reimbursement policy context (access required).
[4] Industry market reports. (N/A). US epinephrine auto-injector market structure and competitive landscape (access required).